What is Forge Biologics?
Founded in 2020 and headquartered in Ohio, United States, Forge Biologics operates at the intersection of contract manufacturing and therapeutic development, with a specialized focus on gene therapy. The company aims to accelerate the development and commercialization of novel gene therapies by providing comprehensive manufacturing solutions and leveraging its internal therapeutic development capabilities. This dual approach positions Forge Biologics as a key player in the rapidly expanding gene therapy market, addressing critical needs in advanced biologics production and innovation.
How much funding has Forge Biologics raised?
Forge Biologics has raised a total of $330M across 4 funding rounds:
Series A
$40M
Series B
$120M
Debt
$80M
Series C
$90M
Series A (2020): $40M with participation from Perceptive Xontogeny Venture Fund
Series B (2021): $120M led by RA Capital Management, Perceptive Advisors, Surveyor Capital, Marshall Wace, and Octagon Capital
Debt (2022): $80M supported by MidCap Financial
Series C (2022): $90M featuring Aisling Capital and Drive Capital
Key Investors in Forge Biologics
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies, with a focus on biopharmaceutical development.
Drive Capital
Drive Capital is a venture capital firm based in Columbus that invests in exceptional founders creating the next generation of market-defining companies, providing capital and support across various industries.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
What's next for Forge Biologics?
The recent major strategic investment in Forge Biologics signals a strong confidence from its backers in the company's future growth and its capacity to scale operations. This infusion of capital is expected to fuel further expansion of its manufacturing capabilities, support ongoing therapeutic development programs, and potentially broaden its market reach. As Forge Biologics continues to mature, its strategic financing will likely enable it to tackle more complex manufacturing challenges and advance its pipeline of gene therapy candidates, solidifying its role as a significant contributor to the biopharmaceutical industry.
See full Forge Biologics company page
